REGN
Annual Meeting of Shareholders
Friday, June 8, 2007 BiopharmaWatch Research 1 min read Key Takeaway: Annual Meeting of Shareholders
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
Annual Meeting of Shareholders.